| Code | CSB-AP005061HU |
| Abbreviation | Recombinant Human CD19 protein, partial (Active) |
| MSDS | |
| Size | $204 |
| Order now | |
| Image | |
| Have Questions? | Leave a Message or Start an on-line Chat |
CD19 is a defining B-cell surface marker and a primary target in CAR-T cell therapy development, making high-quality recombinant forms of its extracellular domain essential for therapeutic antibody validation. This construct covers the extracellular domain (aa 20–291) with a C-terminal Fc tag and is produced in mammalian cells to preserve native glycosylation and conformational integrity critical for accurate epitope recognition. Functional ELISA confirms robust binding to immobilized FMC63 antibody with an ED50 of 55.28 ng/ml, directly supporting use as a positive control in binding assays, CAR-T binder screening, competitive inhibition studies, and epitope mapping of anti-CD19 therapeutics. Purity exceeding 95% by SDS-PAGE combined with endotoxin levels below 1.0 EU/μg satisfies the quality thresholds commonly required for SPR- or BLI-based affinity characterization and cell-based functional assays.
There are currently no reviews for this product.